Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

36/433 Publications

Letter Clear all
  1. Toward non-invasive assessment strategies in autoimmune hepatitis.

    Jerez Diaz D et al. · World J Hepatol · 2025

    ActiTest FibroTest AIH

  2. Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.

    Poynard T et al. · Clin Gastroenterol Hepatol · 2023

    FibroTest Metabolic

  3. Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.

    Herman M et al. · Aliment Pharmacol Ther · 2017

    FibroTest HCV

  4. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017

    FibroTest Other

  5. Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?

    Ofei SY et al. · Int J Cardiol · 2015

    FibroTest Other

  6. Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.

    Munteanu M et al. · Am J Gastroenterol · 2014

    FibroTest HBV

  7. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.

    Poynard T et al. · Ann Intern Med · 2013

    FibroTest HCV

  8. Commentary: prognostication of chronic hepatitis B - are Fibrotest and Fibroscan the final answers? Authors' reply.

    de Lédinghen V et al. · Aliment Pharmacol Ther · 2013

    FibroTest HBV

  9. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.

    Festi D et al. · Aliment Pharmacol Ther · 2013

    FibroTest Metabolic

  10. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.

    Munteanu M et al. · Aliment Pharmacol Ther · 2013

    FibroTest Metabolic

  11. FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.

    Munteanu M et al. · J Hepatol · 2011

    FibroTest HBV HCV HIV

  12. Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis.

    Munteanu M et al. · Scand J Infect Dis · 2011

    ActiTest FibroTest HCV

  13. The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.

    Munteanu M et al. · Am J Gastroenterol · 2011

    FibroTest HCV

  14. Evaluation of FibroTest inter-laboratory variations requires standardization on analytical systems and should not be mixed with underpowered histological validation.

    Munteanu M et al. · Clin Chim Acta · 2010

    FibroTest HCV

  15. Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.

    Poynard T et al. · Aliment Pharmacol Ther · 2009

    FibroTest HCV

  16. Combination of fibrosis tests: sequential or synchronous?

    Boursier J et al. · Hepatology · 2009

    FibroTest HCV

  17. Liver biopsy: the best standard...when everything else fails.

    Poynard T et al. · J Hepatol · 2009

    FibroTest Alcohol HBV HCV +1

  18. The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests".

    Munteanu M et al. · Gastroenterol Clin Biol · 2009

    FibroTest HCV

  19. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.

    Morra R et al. · Hepatology · 2008

    FibroTest Alcohol HBV HCV

  20. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence.

    Poynard T et al. · J Viral Hepat · 2008

    FibroTest HCV

  21. Implementing non-invasive markers for liver fibrosis in clinical practice.

    Sebastiani G et al. · J Hepatol · 2008

    FibroTest HCV

  22. Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations.

    Munteanu M et al. · Clin Biochem · 2008

    FibroTest Alcohol HBV HCV +1

  23. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.

    Adler M et al. · Hepatology · 2008

    FibroTest Alcohol HBV HCV +1

  24. The use of enzyme results for liver fibrosis evaluation neccessitates standardization.

    Myara A et al. · Hepatology · 2008

    FibroTest HBV HCV HIV

  25. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?

    Castera L et al. · J Hepatol · 2007

    FibroTest HCV

  26. External validation of FibroIndex.

    Halfon P et al. · Hepatology · 2007

    FibroTest HCV

  27. Diagnostic value of FibroTest with normal serum aminotransferases.

    Poynard T et al. · Hepatology · 2006

    FibroTest HCV

  28. FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.

    Vallet-Pichard A et al. · Hepatology · 2006

    FibroTest HCV

  29. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases.

    Castera L et al. · Hepatology · 2006

    FibroTest HCV

  30. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?

    Poynard T et al. · Gastroenterology · 2005

    ActiTest FibroTest Alcohol HBV +3

  31. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.

    Le Calvez S et al. · Hepatology · 2004

    FibroTest HCV

  32. Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C.

    Poynard T · Gut · 2003

    HCV

  33. Noninvasive prediction of fibrosis in patients with chronic hepatitis C.

    Thabut D et al. · Hepatology · 2003

    FibroTest HCV

  34. Clinical applicability of non-invasive markers for liver fibrosis in chronic hepatitis C (Letter)

    FibroTest HCV

  35. Poynard T, Imbert-Bismut F, Ratziu V, Myers RP, Di Martino V, Thabut D, Moussalli J, Benhamou Y

    ActiTest FibroTest HCV

  36. Poynard T, Ratziu V, Imbert-Bismut F, Munteanu M

    ActiTest FibroTest HCV

Showing the full result list. The page is server-rendered and not paginated.